Fungal Skin Infections (Tinea) in India: Why They Keep Coming Back

If you practise anywhere in India — in a city or a semi-rural setting, in a general OPD or a dedicated dermatology clinic — you have seen tinea. Almost certainly, you have seen the same patient return with it more than once. The question that should follow every relapsing tinea case is not “which antifungal should I prescribe this time” but “why did this come back.”

India’s tinea burden has become a subject of specific concern in dermatology literature over the past decade, with Indian dermatologists documenting a pattern of recalcitrant, frequently recurrent dermatophytosis that appears to be more difficult to treat than the same presentations in previous decades. The reasons for this — climate, steroid misuse, treatment gaps, and emerging antifungal resistance — are discussed in this article at the level a general practitioner needs to understand to manage these cases more effectively.

This is a two-part clinical discussion. Day 2 covers the full landscape of tinea in India — types, recurrence drivers, and general management principles. Day 3 goes deeper into the single most important driver of recurrence in the current Indian context: steroid-modified tinea and what it means for recognition, management, and outcome. That article is linked at the end of this one.

The Rising Burden of Fungal Skin Infections in India

Dermatophytosis — fungal infection of the skin, hair, and nails caused by dermatophyte fungi — is one of the most common infectious skin conditions globally. In India, it consistently ranks among the top presentations in both general practice and dermatology OPDs. The reported proportion of skin OPD attendances attributable to fungal infections in Indian studies typically ranges between 20–30%, with significant seasonal variation peaking during and immediately after the monsoon months (June–September).

What has changed in recent years is not the frequency of presentation but the clinical behaviour. Indian dermatologists have documented a marked increase in presentations that are recurrent, widespread, and poorly responsive to standard antifungal regimens that previously worked reliably. Published case series and surveillance data from Indian dermatology centres have identified a specific organism — Trichophyton indotineae — as a newly characterised species that has emerged from the Indian subcontinent and shows elevated minimum inhibitory concentrations (MICs) to terbinafine, the most widely used oral antifungal for tinea in this country.

The emergence of T. indotineae is not independent of clinical practice patterns — it is directly connected to the widespread misuse of topical corticosteroid-containing antifungal combination products and inadequate treatment courses, both of which have created selection pressure for resistant organisms. This is a public health-level problem with clinical-level consequences for every GP managing tinea.

Common Types: Tinea Corporis, Cruris, Capitis and Unguium

Tinea is named by anatomical site. The same causative organisms — primarily Trichophyton rubrum and Trichophyton mentagrophytes complex, increasingly T. indotineae in India — can infect different sites with different morphological presentations.

Why Recurrence Is So Common in Indian Patients

Tinea recurrence is not a patient compliance problem, though compliance plays a role. It is predominantly a systems-level problem — a combination of environmental conditions, product availability, prescribing habits, and health system access that creates near-ideal conditions for dermatophytes to persist, reinfect, and develop resistance.

1. Climate and environmental load

Dermatophytes are keratinophilic fungi that thrive at temperatures between 25–37°C and high ambient humidity. India’s tropical and subtropical climate provides these conditions through a significant portion of the year, and the monsoon months create conditions where sweating, skin maceration, and occlusive clothing converge. Unlike temperate climates where tinea is a seasonal problem, India provides near-continuous environmental conditions that support dermatophyte survival on skin, clothing, and environmental surfaces.

2. Inadequate treatment duration

Clinical clearance and mycological cure are not the same event. A tinea lesion may appear visually clear — no active scaling, no erythema — while viable fungal elements remain in the stratum corneum. Standard guidelines recommend continuing antifungal treatment for one to two weeks beyond clinical clearance for skin tinea, and significantly longer for nail and scalp presentations. Most patients stop treatment at clinical clearance, which typically precedes mycological cure by one to two weeks. This leaves a residual fungal load that reactivates under favourable conditions.

3. Untreated reservoir sites

A patient treated for tinea cruris who also has tinea pedis and onychomycosis of the toenails will reliably relapse — because the nail and toe web spaces remain active fungal reservoirs that reinfect the groin through autoinoculation. Treating the visible symptomatic site while leaving reservoir sites untreated is one of the most common reasons for recurrent tinea presentations. A complete evaluation should identify all involved sites — including nails, toe web spaces, and scalp — even when the patient presents with a single lesion elsewhere.

4. Household and close-contact transmission

Dermatophytes are transmitted by direct contact with infected individuals and through contaminated fomites — towels, bed linen, shared clothing, and floor surfaces in communal areas. A treated patient reinfected from an untreated household contact will present as a “recurrence” — the source of infection has not been addressed. Asking specifically about household members with similar skin lesions, and advising simultaneous evaluation and treatment of affected contacts, is a meaningful clinical intervention that most GP consultations omit.

5. Topical corticosteroid misuse — the dominant driver

This deserves extended discussion — see Section 6 and the dedicated Day 3 article on steroid-modified tinea in India. In brief: topical steroids suppress the visible inflammatory response to dermatophyte infection, causing clinical resolution that is entirely superficial. The organism remains viable and continues to grow under the steroid-modified surface. When the steroid is stopped, the full inflammatory response returns — often more severely than the initial presentation. This cycle creates the impression of a highly recurrent infection that is actually a single continuously active infection masked and sustained by repeated steroid application.

General Principles of Correct Antifungal Management

The following are management principles rather than specific prescribing instructions. No drug dosages are provided here — consult current dermatology guidelines (IADVL guidelines, IJDVL consensus statements) and prescribing references for dosing. The principles are applicable across antifungal classes.

Principle 1: Match the route of treatment to the site

Topical antifungals are appropriate for localised tinea corporis and cruris with limited extent. Oral antifungals are indicated for: extensive or widespread tinea; tinea capitis (topicals do not penetrate the hair shaft — oral treatment is non-negotiable here); tinea unguium (topicals achieve inadequate nail penetration for curative treatment in most presentations); recurrent or recalcitrant presentations; and immunocompromised patients. The clinical mistake of using topical antifungal alone for tinea capitis or onychomycosis is one of the most predictable reasons for treatment failure.

Principle 2: Treat for longer than clinical clearance

Clinical clearance — no visible scale, no active erythema — is not the treatment endpoint. Continue topical antifungals for one to two weeks beyond clinical clearance for standard tinea corporis and cruris. Tinea unguium requires extended courses measured in months for both topical and oral regimens, with regrowth of a clear nail as the endpoint rather than symptom resolution. Communicate this duration explicitly to patients at the first consultation — a patient who stops treatment when the lesion looks better will relapse, and will correctly report that “the treatment worked for a while but the infection came back.”

Principle 3: Assess and treat all active sites

Examine the nails, interdigital web spaces, and scalp in any patient presenting with recurrent tinea at other sites. Identify and treat all active sites concurrently. For extensive multi-site involvement, oral antifungals with an appropriate duration are more practical and reliable than attempting to cover multiple sites with topical regimens simultaneously.

Principle 4: Identify and stop any ongoing steroid exposure

Before starting antifungal treatment in any recurrent or extensive tinea presentation, take a specific history of topical products applied to the affected area. Ask directly about branded fairness creams, steroid-containing combinations (often sold OTC as antifungal-steroid-antibiotic triple combinations), and any prescribed topical steroids applied to the skin. An antifungal regimen applied concurrently with a topical corticosteroid is not a treatment — it is a futile attempt to outcompete ongoing steroid-induced fungal amplification.

Principle 5: Consider resistance in non-responsive cases

In cases that do not respond to a correctly administered, adequately dosed oral antifungal course of appropriate duration, consider the possibility of terbinafine-resistant T. indotineae and refer to a dermatologist. These cases require mycological confirmation (KOH, culture with speciation) and antifungal susceptibility testing to guide appropriate management — they are beyond the scope of empirical GP management.

Lifestyle and Hygiene Factors That Worsen Recurrence

Patient counselling on lifestyle and hygiene is a clinical intervention in tinea management — not a supplementary discussion. The dermatophyte’s ability to survive and reinfect is directly influenced by the skin’s moisture and temperature environment, and many patients are inadvertently maintaining conditions that promote fungal persistence despite effective antifungal treatment.

The Hidden Driver: Topical Steroid Misuse (Preview)

The most clinically significant driver of recurrent and difficult-to-treat tinea in India today is not climate, not patient compliance, and not antifungal quality — it is the widespread use of topical corticosteroid-containing products on active fungal infections. This practice is so common in Indian clinical settings that Indian dermatologists have characterised the resulting presentations as a distinct clinical entity: steroid-modified tinea, sometimes called tinea incognito.

Managing a patient with steroid-modified tinea correctly requires recognising the pattern — which is specifically challenging because it does not look like textbook tinea — and withdrawing the steroid as part of the treatment plan rather than replacing it with a different formulation. The antifungal management principles covered in Section 4 apply, but the clinical challenge is compounded by the need to manage steroid withdrawal reactions alongside the fungal infection.

The next article in this dermatology cluster covers steroid-modified tinea in full: its pathophysiology, recognition, the withdrawal decision, and management. Read the complete clinical discussion at steroid-modified tinea in India.

Related guides and programs

Frequently Asked Questions

Why does tinea keep coming back even after treatment?

The most common reasons are: treatment stopped at clinical clearance before mycological cure; untreated reservoir sites (nails, toe web spaces) acting as reinfection sources; ongoing application of topical steroids that suppress symptoms without eradicating the organism; household contact reinfection; and, increasingly, infection with terbinafine-reduced-sensitivity T. indotineae. Identify which mechanism applies before repeating the same treatment.

Can tinea corporis be treated with topical antifungals alone?

For limited, localised tinea corporis without nail or scalp involvement, topical antifungals are first-line. Oral antifungals are indicated for extensive or widespread disease, recurrent presentations, evidence of nail or scalp involvement, failure of topical treatment, and immunocompromised patients. Tinea capitis and onychomycosis always require systemic treatment — topicals are inadequate for these sites.

How long should antifungal treatment continue?

For topical treatment of tinea corporis and cruris, continue for one to two weeks beyond clinical clearance. For oral antifungals, duration depends on the site and severity — nail tinea requires months, not weeks. Stopping at symptom resolution (before mycological cure) is the single most common reason for relapse. Specific duration should follow current IADVL or international dermatology guidelines rather than a generic course length.

What is Trichophyton indotineae and why does it matter?

Trichophyton indotineae is a species of dermatophyte that has been characterised and named from isolates collected predominantly in India and the Indian subcontinent. It shows elevated MICs to terbinafine — the most widely used oral antifungal for tinea in India — compared to other Trichophyton species. This means standard terbinafine courses at standard durations may be insufficient for eradication. Suspected T. indotineae cases should be referred to a dermatologist for mycological confirmation and appropriate antifungal selection.

Should household contacts be treated simultaneously?

Yes, where active tinea is present in household contacts. Shared towels, bedding, and clothing transmit dermatophytes effectively in close-contact living situations. A patient successfully treated who is then reinfected by an untreated household member with active tinea will correctly report recurrence — even though the treatment was effective and complete. Ask about household contacts at every tinea consultation and advise evaluation of symptomatic members.